SCHEMBL5135916

SCHEMBL5135916

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1cc(OC)ccc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
C5AR1 P21730 1/20 0.40
BCHE P06276 5/20 0.39
ACHE P22303 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HSP90AA1 P07900 2/20 0.39
HSP90AB1 P08238 2/20 0.39
ERBB2 P04626 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135241 0.97 C5AR1 (0.42) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5136649 0.95 LMNA (0.43) TP53GAASMN1; SMN2C5AR1LMNA
SCHEMBL5137859 0.94 ALDH1A1 (0.41) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5135642 0.94 C5AR1 (0.42) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5137886 0.92 GNRHR (0.41) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5134702 0.91 ALDH1A1 (0.42) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5135102 0.91 C5AR1 (0.42) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5135095 0.91 BCHE (0.47) TP53GAASMN1; SMN2C5AR1BCHE
SCHEMBL5072272 0.89 GAA (0.43) GAAC5AR1BCHEKDM4EALDH1A1
SCHEMBL5136651 0.89 C5AR1 (0.43) TP53GAASMN1; SMN2C5AR1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed